On the Management of Drug Interactions in the Course of Concomitant Treatments for COVID-19 and Antineoplastic Agents

• Nicola Silvestris,
• Nicola Silvestris,
• Antonio Munafò,
• Oronzo Brunetti,
• Chiara Burgaletto,
• Luisa Scucces,
• Renato Bernardini

Affiliations

Nicola Silvestris

Medical Oncology Unit, IRCCS Istituto Tumori “Giovanni Paolo II”, Bari, Italy

Nicola Silvestris

Department of Biomedical Sciences and Human Oncology, University of Bari “Aldo Moro”, Bari, Italy

Antonio Munafò

Section on Pharmacology, Department of Biomedical and Biotechnological Sciences, University of Catania School of Medicine, Catania, Italy

Oronzo Brunetti

Medical Oncology Unit, IRCCS Istituto Tumori “Giovanni Paolo II”, Bari, Italy

Chiara Burgaletto

Section on Pharmacology, Department of Biomedical and Biotechnological Sciences, University of Catania School of Medicine, Catania, Italy

Luisa Scucces

Section on Pharmacology, Department of Biomedical and Biotechnological Sciences, University of Catania School of Medicine, Catania, Italy

Renato Bernardini

Section on Pharmacology, Department of Biomedical and Biotechnological Sciences, University of Catania School of Medicine, Catania, Italy